Science

Elvina Almuradova: JAVELIN Renal 101 Phase 3 Trial Results by Toni Choueiri et al.

Collage photo of Elvina Almuradova and Toni Choueiri

Dec 20, 2024, 14:04

Elvina Almuradova: JAVELIN Renal 101 Phase 3 Trial Results by Toni Choueiri et al.

A recent paper by Toni Choueiri, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, published in Annals of Oncology, was mentioned by Elvina Almuradova, Associate Professor at Medicana Health Group, on X:

“JAVELIN Renal 101 Phase 3 Trial Results:

Avelumab and Axitinib showed better progression-free survival (PFS) and nearly double the objective response rate (ORR) vs. sunitinib in advanced renal cell carcinoma (aRCC).
Median overall survival (OS): 43.2 months vs. 36.2 months (HR 0.86, p=0.0755). OS did not reach statistical significance.
5-year event-free rate: 12% vs. 4.4% with sunitinib.
ORR: 59.7% vs. 32%.
Durable responses: ≥5 years in 16.4% of avelumab and axitinib patients.

Avelumab and axitinib showed long-term benefits, including improved PFS, ORR, and durability.”

Avelumab + axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase 3 JAVELIN Renal 101 trial

Authors: Toni Choueiri et al.

Elvina Almuradova: JAVELIN Renal 101 Phase 3 Trial Results by Toni Choueiri et al.

Toni Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School.

As a medical oncologist, clinical trialist, and translational researcher, he specializes in treating genitourinary cancers (prostate, bladder, testis, and kidney cancer), with a focus on kidney cancer.